JPM
JPMorgan Chase & Co.
JPM has the edge over USCB overall, supported by stronger fundamentals and stronger modeled upside.
USCB
USCB Financial Holdings, Inc.
USCB offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
JPM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
JPM's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like JPM.
USCB Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| N/A | |
| N/A |
USCB's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like USCB.
JPM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $231 | -33% |
| Fair | 12x | $287 | -16% |
| Current | 14x | $343 | — |
| Forward | 14x | $343 | — |
| Expensive | 15x | $361 | +5.2% |
Historical ranges are pointers, not guarantees.
JPM's PE is in its expensive range at 14.4x. If earnings grow as analysts expect, today's price would be 13.7x next year's earnings.
USCB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.8x | $20.13 | — |
| Cheap | 11x | $18.10 | -10% |
| Fair | 13x | $20.88 | +3.7% |
| Current | 13x | $20.13 | — |
| Expensive | 17x | $26.97 | +34% |
Historical ranges are pointers, not guarantees.
USCB has the edge over JPM in the historical PE scenario, which offers more potential upside but is not a forecast.
JPM Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for JPM, with profitability improving.
USCB Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect USCB's revenue to grow, but its profitability to weaken.
JPM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.99 | +4.8% |
| Q3 2026 | $23.85 | +18% |
| Q2 2026 | $23.35 | +20% |
| Q1 2026 | $20.89 | +2.5% |
| Q4 2025 | $20.02 | +1.4% |
| Q3 2025 | $20.20 | +12% |
| Q2 2025 | $19.50 | +8.7% |
| Q1 2025 | $20.38 | +23% |
| Q4 2024 | $19.75 | +22% |
JPM's earnings per share have climbed steadily: $23.85 over the past year, up 18% from the year before, and higher year over year for 15 quarters in a row.
USCB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.05 | +27% |
| Q3 2026 | $1.61 | +1.9% |
| Q2 2026 | $1.55 | +4.7% |
| Q1 2026 | $1.46 | +5% |
| Q4 2025 | $1.33 | +7.3% |
| Q3 2025 | $1.58 | +52% |
| Q2 2025 | $1.48 | +68% |
| Q1 2025 | $1.39 | +78% |
| Q4 2024 | $1.24 | +48% |
USCB has the edge over JPM on earnings, with stronger typical year-over-year growth.
JPM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2B | +8.1% |
| Q2 2026 | $57.3B | +28% |
| Q1 2026 | $49.8B | +10% |
| Q4 2025 | $45.8B | +7.1% |
| Q3 2025 | $46.4B | +8.8% |
| Q2 2025 | $44.9B | -11% |
| Q1 2025 | $45.3B | +8.1% |
| Q4 2024 | $42.8B | +11% |
JPM's revenue has grown year over year for five quarters in a row: $50.2B last quarter, up 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | -0.2 points |
| Q2 2026 | 48% | +7.3 points |
| Q1 2026 | 41% | +0.5 points |
| Q4 2025 | 37% | -3.2 points |
| Q3 2025 | 40% | +0.6 points |
| Q2 2025 | 41% | -6 points |
| Q1 2025 | 41% | -0.6 points |
| Q4 2024 | 41% | +11 points |
JPM's operating margin was 40% last quarter, about level with the same quarter a year ago.
USCB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $27M | +8.1% |
| Q2 2026 | $27.9M | +15% |
| Q1 2026 | $26.2M | +15% |
| Q4 2025 | $18M | -22% |
| Q3 2025 | $25M | +16% |
| Q2 2025 | $24.4M | +19% |
| Q1 2025 | $22.8M | +30% |
| Q4 2024 | $23M | +46% |
USCB has the edge over JPM on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 45% | -2.1 points |
| Q2 2026 | 45% | +1.5 points |
| Q1 2026 | 45% | +0.4 points |
| Q4 2025 | 18% | -21 points |
| Q3 2025 | 47% | +4.8 points |
| Q2 2025 | 44% | +4.2 points |
| Q1 2025 | 44% | +10 points |
| Q4 2024 | 40% | +17 points |
USCB has the edge over JPM on profitability, with a higher operating margin.
JPM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33.2B | +$78.4B |
| Q2 2026 | -$25.3B | -186% |
| Q1 2026 | -$211.8B | +$40.1B |
| Q4 2025 | $119.7B | -19% |
| Q3 2025 | -$45.2B | +$28.9B |
| Q2 2025 | $29.5B | -23% |
| Q1 2025 | -$251.8B | -$97.7B |
| Q4 2024 | $147.8B | +145% |
JPM's free cash flow was −$84.2B over the past year, against −$120B the year before. Free cash flow isn't a meaningful measure for financial services companies like JPM.
USCB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $13.9M | -30% |
| Q2 2026 | $24.2M | +35% |
| Q1 2026 | $15M | +2.6% |
| Q4 2025 | -$10.1M | -$7M |
| Q3 2025 | $20M | +80% |
| Q2 2025 | $18M | +1% |
| Q1 2025 | $14.6M | +84% |
| Q4 2024 | -$3.1M | +$2.9M |
USCB has the edge over JPM on cash generation, producing positive trailing cash flow while its opponent burns cash.
JPM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -11.2M shares |
| 1 year | -3.1% | -84.6M shares |
| 3 years | -8.5% | -249M shares |
| 5 years | -11% | -322M shares |
| Available history | -17% | -547M shares |
JPM has the edge over USCB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1B |
| Q2 2026 | $6.8B |
| Q1 2026 | $8.3B |
| Q4 2025 | $8.3B |
| Q3 2025 | $8.3B |
| Q2 2025 | $7.5B |
| Q1 2025 | $7.5B |
| Q4 2024 | $4.3B |
JPM spent $24.5B buying back its own shares over the past year, down 11% from the year before.
USCB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -88.3K shares |
| 1 year | +1.5% | +276K shares |
| 3 years | -5.9% | -1.2M shares |
USCB has 18M diluted shares, up 1.5% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $1M |
| Q4 2025 | — |
| Q3 2025 | $34.4M |
| Q2 2025 | — |
| Q1 2025 | $174,000 |
| Q4 2024 | — |
USCB spent $1M buying back its own shares over the past year, down 97% from the year before.
JPM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.5x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.4x | Very low |
JPM's net debt is less than a year of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like JPM.
USCB Net Leverage
JPM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.5 | Neutral |
JPM's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
USCB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.9 | Neutral |
| Stochastic | 14.9 | Oversold |
USCB's weekly RSI is 44 (neutral) and its Stochastic is 15 (oversold).
JPM PE vs Financial Services Sector
| Metric | JPM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 13x | 10% above |
| PE % | 76 | 63 | 13 pts above |
JPM is trading at 14x earnings, a 10% premium to the Financial Services sector's median of 13x.
USCB PE vs Financial Services Sector
| Metric | USCB | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 13x | 4% below |
| PE % | 43 | 66 | 23 pts below |
USCB has the edge over JPM on valuation relative to its sector.
JPM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $336.8 | 1.8% above |
| 20 week MA | $345.3 | 0.7% below |
| 50 week MA | $323.2 | 6.1% above |
| 100 week MA | $298.9 | 15% above |
| 200 week MA | $236.6 | 45% above |
JPM has the edge over USCB on trend strength, trading above more of its moving averages.
USCB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.2 | 4.9% below |
| 20 week MA | $21.7 | 7.1% below |
| 50 week MA | $20.1 | 0.3% above |
| 100 week MA | $18.7 | 7.4% above |
| 200 week MA | $15.6 | 29% above |
USCB has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 29% above its 200-week average.
JPM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $139.1 | $124.5 | -11% |
| 2021 | $124.5 | $157.3 | +26% |
| 2022 | $157.3 | $131.3 | -17% |
| 2023 | $131.3 | $170.1 | +30% |
| 2024 | $170.1 | $241.2 | +42% |
| 2025 | $241.2 | $327.9 | +36% |
| 2026 YTD | $327.9 | $342.8 | +4.5% |
JPM has finished higher in four of the last six years. It's up 4.5% so far in 2026.
USCB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $10.8 | $14.6 | +35% |
| 2022 | $14.6 | $12.5 | -15% |
| 2023 | $12.5 | $12.3 | -1.7% |
| 2024 | $12.3 | $17.7 | +45% |
| 2025 | $17.7 | $18.7 | +5.8% |
| 2026 YTD | $18.7 | $20.1 | +7.5% |
USCB has the edge over JPM on returns for 2026, with the stronger performance.